What are the characteristics of ARGENX SE stock?

ARGENX SE is a company operating in the Santé · Biotechnologies · Vaccins et laboratoires de recherche sector. The stock is listed on Euronext Brussels under ISIN NL0010832176.

What is the recent price evolution of ARGENX SE stock?

Since last close: 5.1 %. Over one week: 6.54 %. Over one year: 50.79 %.

Argenx to Participate in TD Cowen's Annual Health Conference

Argenx announces the participation of its Chief Operating Officer in a presentation at the 46th annual TD Cowen Health Conference. The event will take place on March 2, 2026.

Published on Feb 23, 2026 at 08:24

Argenx to Participate in TD Cowen's Annual Health Conference

ARGENX SE

766.00 € +5.10 %

Presentation Details

Karen Massey, Chief Operating Officer of argenx, will participate in a discussion session at the 46th annual TD Cowen Health Conference on Monday, March 2 at 11:50 AM Eastern Time. This presentation will be broadcast live on the Investors section of the argenx website.

Webcast Availability

Free · Every morning

Technical market signals, before the opening bell.

Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.

✓ Before 9 AM every morning ✓ Euronext data ✓ AI-powered analysis

Indicative data. No investment advice. Unsubscribe at any time.

A replay of the webcast will be available on the argenx website for approximately 30 days following the presentation.

🏢 Other stocks — Santé

🗞️ Ipsen's Stock Rebounds Over 2%, Marking One of the Top Gains in SBF 120 🗞️ Valneva's Shares Continue to Fall, Threatening Key Support at €2.26 🗞️ DBV Technologies Shares Drop Nearly 4% Breaking Below 200-Day Moving Average 🗞️ Sanofi Shares Lead the CAC 40, Surpassing €78

Context

Period

Period: 1T2026

Key reported figures

Revenue: 1.3MD€
Net income: 366M€

Guidance from the release

argenx continue de livrer un impact significatif pour les patients.
Argentx affiche une croissance de 63% par rapport à l'année précédente.

Risks mentioned

Les résultats peuvent varier en fonction des incertitudes liées aux essais cliniques.
L'impact des lois et règlements gouvernementaux pourrait affecter les activités.

Opportunities identified

VYVGART pourrait devenir la première thérapie approuvée dans les populations gMG.
Lancement d'une étude pour le candidat pipeline empasiprubart.

The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.

Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.

Presentation Details

Webcast Availability

Context

Also read